Home › IGA Glomerulonephritis › NCT06952426

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

A Mobile App-Based, Prospective, Observational Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Diagnosis of IgAN, regardless of symptom or treatment history
* Adult aged 18 or older; adult caregiver to an adult patient aged 18 or older; or adult caregiver to a pediatric patient under 18 years of age
* US-based with a proficient understanding of and ability to read the English language

Exclusion Criteria:

None

About the study

The study aims to longitudinally capture the full spectrum of symptoms, treatment utilization, and overall health-related quality of life (HRQoL) experienced by Immunoglobulin A nephropathy (IgAN) patients and their caregivers.

What is being tested

• No intervention (other)
• Other treatment (other)
• Iptacopan (other)
• Atrasentan (other)

Sponsor: Novartis Pharmaceuticals · Participants: 300 · Started: Mar 4, 2025

Contact the study team

• Novartis Pharmaceuticals · Phone: +41613241111

Official record on ClinicalTrials.gov — NCT06952426

Locations in the U.S.

Conditions

• IGA Glomerulonephritis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.